1. Signaling Pathways
  2. Neuronal Signaling
  3. Amyloid-β

Amyloid-β

β-amyloid peptide; Aβ; Abeta

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-101861
    Miridesap
    Inhibitor 99.19%
    Miridesap is a ligand for serum amyloid P component (SAP) and intends to inhibit and dissociate SAP binding to amyloid fibrils and tangles.
    Miridesap
  • HY-P990011
    Sabirnetug
    Inhibitor
    Sabirnetug is a humanized IgG2κ antibody targeting the Amyloid-β A4 precursor protein.
    Sabirnetug
  • HY-115726
    FRM-024
    Inhibitor 99.45%
    FRM-024 is a central nervous system-penetrant, orally active γ-secretase modulator and Aβ42 lowering agent. FRM-024 is used for the research of familial Alzheimer's disease.
    FRM-024
  • HY-B1794A
    Thiethylperazine dimaleate
    Inhibitor 99.99%
    Thiethylperazine dimaleate, a phenothiazine derivate, is an orally active and potent dopamine D2-receptor and histamine H1-receptor antagonist. Thiethylperazine dimaleate is also a selective ABCC1activator that reduces amyloid-β (Aβ) load in mice. Thiethylperazine dimaleate has anti-emetic, antipsychotic and antimicrobial effects.
    Thiethylperazine dimaleate
  • HY-128849
    Eprodisate (70% in water)
    Inhibitor ≥98.0%
    Eprodisate (70% in water) is an amyloid inhibitor that interferes with the interaction between amyloidogenic proteins and glycosaminoglycans, thereby inhibiting the aggregation of amyloid fibrils and the deposition of fibrils in tissues. Eprodisate (70% in water) slows the progression of renal disease associated with AA amyloidosis and may be useful for other types of amyloidosis.
    Eprodisate (70% in water)
  • HY-174806
    Y040-7904
    Inhibitor 99.36%
    Y040-7904 is a mitophagy activator. Y040-7904 enhances mitophagy by promoting mitochondria transport to autophagosomes and the fusion of autophagosomes with autolysosomes. Y040-7904 induces mitophagy through the SIRT1/FoxO3 pathway. Y040-7904 upregulates the levels of Parkin, PINK1, and LC3II/I. Y040-7904 reduces amyloid-β () accumulation in both in vitro and in vivo models of Alzheimer’s disease.
    Y040-7904
  • HY-P6306A
    CS-6253 TFA
    Inhibitor 98.08%
    CS-6253 TFA is an agonist of ABCA1. CS-6253 TFA can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 TFA also has certain neuroprotective effects and can clear from the brain. CS-6253 TFA can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease.
    CS-6253 TFA
  • HY-14562
    TBPB
    Inhibitor 99.74%
    TBPB (tert-butyl peroxybenzoate) is a highly selective, blood-brain-permeable M1 mAChR allosteric agonist (EC50=289 nM) with anti-schizophrenia and anti-inflammatory activities. TBPB can enhance the sensitivity of M1 receptors to acetylcholine, activate downstream signaling pathways, and inhibit the release of pro-inflammatory cytokines (TNF-α, IL-6). TBPB can regulate the processing of amyloid and can be used in the study of neurodegenerative diseases (such as Alzheimer's disease) and inflammation-related diseases (such as sepsis).
    TBPB
  • HY-171348
    Amyloid-β-IN-2
    Inhibitor 99.47%
    Amyloid-β-IN-2 (Compound EX.112) is a selective γ-secretase inhibitor. Amyloid-β-IN-2 inhibits Aβ42 secretion in H4 cells with an EC50 value of 226 nM. Amyloid-β-IN-2 is promising for research of Alzheimer's disease (AD) and other diseases related to Aβ deposition.
    Amyloid-β-IN-2
  • HY-161725
    TFEB activator 3
    Inhibitor 98.94%
    TFEB activator 3 (compound 45) exhibits TFEB activation and lysosome biogenesis capabilities. TFEB activator 3 has effect on TFEB nuclear translocation with 44% (10μM 3h) and 97 % (30 μM 3h). TFEB activator 3 plays an important role in Alzheimer’s disease (AD). TFEB activator 3 can pass blodd brain barrier.
    TFEB activator 3
  • HY-171349
    Amyloid-β-IN-3
    Inhibitor 99.50%
    Amyloid-β-IN-3 (EX.113) is a selective γ-secretase inhibitor. Amyloid-β-IN-3 inhibits Aβ42 secretion in H4 cells with an EC50 value of 148 nM. Amyloid-β-IN-3 regulates the γ-secretase catalytic activity to decrease Aβ42 production, thereby alleviating neurotoxicity caused by Aβ deposition. Amyloid-β-IN-3 is promising for research of Alzheimer's disease (AD).
    Amyloid-β-IN-3
  • HY-119173
    PBD-150
    Inhibitor 99.53%
    PBD-150 is a human glutaminyl cyclase (hQC) Y115E-Y117E variant inhibitor, with a Ki value of 490 nM.
    PBD-150
  • HY-P1173
    L803-mts
    Inhibitor 99.98%
    L803-mts (Myristoylated L 803) is a selective and substrate-competitive GSK-3 peptide inhibitor (IC50: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test.
    L803-mts
  • HY-159083
    DN5355
    Inhibitor 99.01%
    DN5355 is a small molecule compound that targets amyloid β protein () and hyperphosphorylated tau protein. DN5355 can inhibit the aggregation of and tau protein and disaggregate the formed and tau protein fibers. DN5355 can be used in the study of Alzheimer's disease.
    DN5355
  • HY-111383
    LX2343
    Inhibitor 99.80%
    LX2343 is a BACE1 enzyme inhibitor with an IC50 value of 11.43±0.36 μM. LX2343 acts as a non-ATP competitive PI3K inhibitor with an IC50 of 15.99±3.23 μM. LX2343 stimulates autophagy in its promotion of clearance.
    LX2343
  • HY-N11709
    Theasaponin E1
    Inhibitor 98.68%
    Theasaponin E1 is an orally effective tea saponin. Theasaponin E1 inhibits the proliferation of cancer cells by activating apoptosis. Theasaponin E1 inhibits angiogenesis in ovarian cancer cells and HUVECs by reducing the expression of VEGF. Theasaponin E1 upregulates the phosphorylation level of ATM protein and the expression level of PTEN protein in cancer cells, decreases the phosphorylation levels of Akt, mTOR, p70S6K and 4E-BP1 proteins, downregulates the expression of HIF-1α and NF-κB, and reduces the protein expression of Notch ligands Dll4 and Jagged1. Theasaponin E1 exerts neuroprotective effects by inhibiting the activity of acetylcholinesterase, activating α-secretase and neprilysin, reducing the concentration of , and inhibiting the activities of β-secretase and γ-secretase. Theasaponin E1 exhibits toxic effects on cancer cells and quinone reductase-inducing activity, and inhibits tumor growth in vivo. Theasaponin E1 induces ferroptosis in Pomacea canaliculata by synergistically disrupting cholesterol homeostasis and sphingolipid metabolism. Theasaponin E1 possesses anti-biofilm activity against Candida albicans. Theasaponin E1 can be used in the research of ovarian cancer, obesity, Alzheimer's disease and fungal infections.
    Theasaponin E1
  • HY-111911
    Xanthocillin X permethyl ether
    Inhibitor 98.90%
    Xanthocillin X permethyl ether is a natural compound isolated from fungal extracts, with Aβ-42 lowering activity.
    Xanthocillin X permethyl ether
  • HY-108499
    NNC 26-9100
    Inhibitor 99.3%
    NNC 26-9100 is a selective somatostatin sst4 receptor full agonist (Ki: 6 nM, EC50: 2 nM). NNC 26-9100 decreases total soluble Aβ42, increases brain neprilysin activity and improves learning.
    NNC 26-9100
  • HY-121811
    Pongamol
    Inhibitor 99.81%
    Pongamol (Lanceolatin C) is an orally active flavonoid with an IC50 of 75 μM and a Ki of 58 μM against PTPase-1B, and an IC50 of 103.5 μM against intestinal α-Glycosidase. Pongamol reduces the release of IL‑1β, TNF‑α, COX‑2 and iNOS in cells, reverses the nuclear translocation of NF‑κB, and upregulates the levels of Beclin 1 and LC3 Ⅱ/LC3 Ⅰ. Pongamol promotes glucose uptake by increasing the level of GLUT4 on the surface of skeletal muscle cells. Pongamol inhibits epithelial-mesenchymal transition by suppressing the FAK/Akt-mTOR signaling pathway. Pongamol inhibits neuronal cytotoxicity, suppresses cell apoptosis and extends the lifespan of Caenorhabditis elegans by activating the MAPKs/Nrf2 signaling pathway. Pongamol exerts hypoglycemic effects in diabetic mouse models. Pongamol exhibits antibacterial activity. Pongamol alleviates oxidative stress, neuroinflammation, deposition and excessive phosphorylation of Tau Protein, and restores autophagy function in Alzheimer's disease mouse models by inhibiting the Akt/mTOR signaling pathway. Pongamol is applicable to research related to Alzheimer's disease, type 2 diabetes, non-small cell lung cancer and postprandial hyperglycemia.
    Pongamol
  • HY-P3244
    D-KLVFFA
    Inhibitor 99.26%
    D-KLVFFA is the inhibitor of Amyloid-β assembly, with the IC50 of 2.6 μM, that can be used in Alzheimer's disease study.
    D-KLVFFA
Cat. No. Product Name / Synonyms Application Reactivity